Clinical trials: Biliary Cancers
Stomach Cancer, Gall Bladder Cancer
Study of Capecitabine and Oxaliplatin in Combination With Radiotherapy in Patients With Unresectable Gastro-Intestinal Cancer
The purpose with this study is to evaluate treatment with radio chemotherapy (oxaliplatin and capecitabine) given concommitant with radiotherapy in patients with gastrointestinal tumors.
- Conditions
- Stomach Cancer, Gall Bladder Cancer, Bile Ductus Cancer, Pancreas Cancer
- Trial name
- CORGI (NCT01016639)
- Testing
- oxaliplatin, capecitabine, radiotherapy
- Where
- 5 sites in Sweden
- Volunteers
- 106 people
- Sponsor
- Lund University Hospital
Choledocholithiasis, Bile Duct Cancer
Loop-tipped Guidewire in Selective Biliary Cannulation
1. Background Advanced guidewires with a U-shaped tip could effectively cross the long or multi-occlusive segment smoothly and go into the distal outflow vessel.
- Conditions
- Choledocholithiasis, Bile Duct Cancer, Pancreatic Cancer, Ampullary Tumor
- Trial name
- NCT02028845
- Testing
- Biliary cannulation with loop guidewire, Biliary cannulation with straight guidewire
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Ajou University School of Medicine
Hepatocellular Carcinoma, Hepatoma
Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery
It has been shown that patients who undergo liver resection surgery are at high risk for postoperative acute kidney injury (AKI). Sevoflurane may increase the risk for postoperative AKI because of production of compound-A.
- Conditions
- Hepatocellular Carcinoma, Hepatoma, Cholangiocarcinoma, Gallbladder Neoplasms
- Trial name
- NCT02174575
- Testing
- Sevoflurane, Desflurane
- Where
- Japan
- Sponsor
- Tokyo Medical and Dental University
Biliary Cancer Metastatic
mFOLFOX/mFOLFIRI vs. mFOLFOX in Advanced or Recurrent Biliary Tract Cancer Second-line
In second line with advanced or recurrent biliary tract cancer refractory to first line gemcitabine plus cisplatin,efficacy of mFOLFOX/FOLFIRI vs mFOLFOX will be evaluated at randomized phase 2 trial.
- Trial name
- NCT07062536
- Testing
- Oxaliplatin, 5FU, leucovorin, Oxaliplatin, 5FU, leucovorin/Irinotecan , 5FU, leucovorin,
- Where
- 11 sites in South Korea
- Volunteers
- 130 people
- Sponsor
- Seoul National University Bundang Hospital
Gallbladder Carcinoma
Comprehensive Genomic Profiling Combined With Real Life Data of "The German-Registry of Incidental Gallbladder Carcinoma"
Multicenter German- Registry of Incidental Gallbladder Carcinoma combining clinical real-world data and comprehensive genomic profiling.
- Trial name
- NCT05222854
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Cholangiocarcinoma, Extrahepatic, Cholangiocarcinoma of the Extrahepatic Bile Duct
Raman Spectroscopy in the Diagnosis of Extrahepatic Cholangiocarcinoma - a Pilot Study
Diagnosis of extrahepatic cholangiocarcinoma is challenging because the yield of imaging and tissue sampling is limited. Raman spectroscopy is an optical method based on the analysis of scattered monochromatic light.
- Conditions
- Cholangiocarcinoma, Extrahepatic, Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma, Perihilar, Diagnosis
- Trial name
- NCT06964425
- Testing
- Endoscopic retrograde cholangiopancreatography (ERCP)
- Where
- Czechia
- Volunteers
- 20 people
- Sponsor
- University Hospital Olomouc
BTC
Chidamide Combined With Benmelstobart, Nab-paclitaxel, and SBRT as Second-Line Treatment for Advanced BTC
This study is a prospective, single-arm, multicenter, exploratory clinical trial. It aims to evaluate the efficacy and safety of chidamide combined with benmelstobart, nab-paclitaxel, and immunogenic radiotherapy (SBRT) as…
- Trial name
- NCT07890506
- Testing
- chidamide+benmelstobart+nab-paclitaxel+SBRT
- Where
- China
- Volunteers
- 41 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Advanced GI Cancer
Phase I Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers
This is a Phase I dose escalation trial to assess MTD of MK-3475 in combination with mFOLFOX6 followed by a safety expansion open label, nonrandomized trial with MK-3475 at MTD in combination with mFOLFOX6 and supplemental…
- Trial name
- MK-3475 GI (NCT02268825)
- Testing
- MK-3475
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Utah
Primary Biliary Cholangitis, Intrahepatic Bile Duct Cancer
Patients With Primary Biliary Cholangitis
Primary biliary cholangitis (PBC) is a chronic autoimmune disease characterized by progressive destruction of the small intrahepatic bile ducts, leading to cholestasis and potential progression to cirrhosis.
- Conditions
- Primary Biliary Cholangitis, Intrahepatic Bile Duct Cancer, Cancer Liver
- Trial name
- BILIFLEX (NCT07573514)
- Testing
- Reflex AMA and ANA testing
- Where
- Italy
- Volunteers
- 2,000 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Cholangiocarcinoma, Gallbladder Cancer
A Study for Efficacy of Side-by-side Compared to Stent-in-stent Technique in the Endoscopic Management of Malignant Hilar Biliary Obstruction
Malignant obstructive jaundice is a common complication of advanced stage cholangiocarcinoma, GB cancer, and pancreatic cancer. In biliary stricture by malignancy, biliary drainage with placement of self-expanding metal stent…
- Conditions
- Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, HCC
- Trial name
- NCT02659852
- Testing
- side by side, stent in stent
- Where
- South Korea
- Volunteers
- 70 people
- Sponsor
- Yonsei University
Inoperable Disease, Bile Duct Cancer
CH-EUS in Diagnosis of Inoperable Bile Duct Tumors
VALIDATION OF THE SUPERIORITY OF CONTRAST ENHANCED ENDOSCOPY TO STANDARD ENDOSCOPY IN THE DIAGNOSIS OF BILE DUCT TUMORS
- Trial name
- NCT05418543
- Testing
- Endoscopic ultrasound with fine needle biopsy
- Where
- Romania
- Volunteers
- 40 people
- Sponsor
- Institutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian Fodor
Biliary Tract Cancer
Second Line Therapy in Advanced Biliary Tract Cancer
The purpose of this study is to assess the therapeutic activity of capecitabine alone or in combination with mitomycin C as second-line therapy in patients with advanced/metastatic biliary adenocarcinoma in progression after…
- Trial name
- BIT-2 (NCT01530503)
- Testing
- capecitabine and mitomycin, Capecitabine
- Where
- 16 sites in Italy
- Volunteers
- 52 people
- Sponsor
- IRCCS San Raffaele
Biliary Tract Neoplasms, Pancreatic Neoplasms
The Efficacy and Safety of Trilaciclib in Bone Marrow Protection Before Chemotherapy for Advanced Bile Duct Cancer and Pancreatic Cancer
Evaluate the efficacy and safety of Trilaciclib for myeloprotection prior to chemotherapy in advanced cholangiocarcinoma or pancreatic cancer.
- Trial name
- NCT07160283
- Testing
- Bile duct cancer cohort, Pancreatic cancer cohort
- Volunteers
- 96 people
- Sponsor
- The Second Affiliated Hospital of Shandong First Medical University
Choledochal Cyst
Host-Microbe Interactions in Biliary Dilatation
This study is an observational cohort study aimed at continuously enrolling patients with biliary dilatation and healthy controls.
- Trial name
- NCT07152496
- Where
- China
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Cholangiocarcinoma, Biliary Stricture
EYEMAX® Versus SPYGLASS™ DS for Biliary Stricture Diagnosis
Cholangiocarcinoma remains difficult to diagnose because of the limited sensitivity of currently available endobiliary sampling techniques.
- Trial name
- EYE/SPY (NCT07620080)
- Testing
- EYEMAX® cholangioscopy system, SPYGLASS™ DS system
- Volunteers
- 120 people
- Sponsor
- David KARSENTI
Gall Bladder Carcinoma
Neoadjuvant Chemotherapy for Locally Advanced Gall Bladder Cancer : a Randomized Control Trial (NEOGB)
to study role of chemotherapy treatment for gall bladder cancer before surgery as compared to surgery directly
- Trial name
- NEOGB (NCT06712420)
- Testing
- neoadjuvant chemotherapy, curative surgery
- Where
- 3 sites in India
- Volunteers
- 114 people
- Sponsor
- Rajiv Gandhi Cancer Institute & Research Center, India
HER2-positive Breast Cancer, HER2 Gene Mutation
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies.
- Conditions
- HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer
- Trial name
- NCT03602079
- Testing
- A166
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Klus Pharma Inc.
Cholangiocarcinoma, Pancreatic Cancer
T-EUS for Gastrointestinal Disorders: A Multicenter Registry
The purpose of this registry is to record information and evaluate the impact of Endoscopic Ultrasound (EUS) Guided Endoscopic retrograde cholangiopancreatography (ERCP) on the management of pancreatico-biliary disorders.
- Conditions
- Cholangiocarcinoma, Pancreatic Cancer, Bile Duct Cancer, Biliary Stricture
- Trial name
- EUSERCPReg (NCT01522573)
- Testing
- EUS guided ERCP
- Where
- 2 sites in United States, Brazil
- Volunteers
- 1,000 people
- Sponsor
- Weill Medical College of Cornell University
Cholangiocarcinoma
Efficacy and Safety of Photodynamic Therapy for Unresectable Cholangiocarcinoma
The aim of this study is to investigate the efficacy of photodynamic therapy (PDT) in increasing the survival time, decreasing cholestasis and improving health-related quality of life (HRQoL) by comparing PDT puls stents versus…
- Trial name
- NCT02585856
- Testing
- PDT, stent
- Where
- China
- Volunteers
- 39 people
- Sponsor
- First People's Hospital of Hangzhou
Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ
CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
The purpose of this study is to determine the safety and tolerability of monotherapy CR-002 and to identify the MTD and/or optimal biologic dose and RP2D(s) in participants with locally advanced or metastatic solid tumors.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ, Biliary Tract Cancer (BTC), Esophageal Squamous Cell Carcinoma (ESCC)
- Trial name
- APOLLO (NCT07909031)
- Testing
- CR-002
- Where
- 3 sites in United States
- Volunteers
- 219 people
- Sponsor
- Crescent Biopharma, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.